Patents cover entirety of sub-$200 test and platform, which isolates rare circulating tumor cells (CTCs) from one tube of blood CellMax Life, enabling early cancer detection and management with ...
SAN DIEGO, July 28, 2011 /PRNewswire/ -- Biocept, Inc., an advanced diagnostic CLIA-certified service laboratory developing novel tests for the oncology community, today announced the availability of ...
A novel blood test for prostate cancer has the potential to significantly improve patient stratification by prostate-specific antigen (PSA) and/or multiparametric MRI for biopsy and treatment, say the ...
An international study led by researchers at The Institute of Cancer Research will pave the way for a test to be used to better tailor treatments and hopefully extend the survival of men with ...
New research supports the use of a circulating tumor cell (CTC) blood test, rather than the standard PSA biomarker diagnostic, to predict a patient's odds of surviving prostate cancer. A team at the ...
A simple blood test that detects tumor cells circulating in the blood shows promise as a new way to predict high or low risk of a breast cancer relapse. This is according to data presented today at ...
Bologna, Italy and Huntingdon Valley, Pa. -- Menarini Silicon Biosystems, the pioneer of liquid biopsy technology, today announced the publication of a research study providing support for the ...
STIC CTC trial data published this November 2023 in the Journal of Clinical Oncology (JCO) demonstrate that CTC-guided treatment decision confers superior survival benefits in a subgroup of patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback